Synopsis
Telehealth company eMed has secured $200 million in funding, boosting its valuation to over $2 billion. This investment will fuel the development of its agentic AI platform. eMed is also introducing a new healthcare payment model designed to reduce employer healthcare expenses.Other prominent investors included Brady, who is also the company's founding chief wellness officer, its CEO Linda Yaccarino, as well as Paragon Biosciences founder and CEO Jeff Aronin, among others, eMed said.
Founded in 2020, eMed gained traction during the pandemic with at-home COVID-19 tests and later expanded into diagnostics for strep throat and UTIs, though it has since moved away from those offerings.
"The raise confirms eMed momentum and establishes us as the definitive company for population health and helping employers break the runaway health care costs and break their cost curve," eMed CEO Linda Yaccarino, who was the former chief executive of social media platform X, said in an interview on FOX Business Network.
